AAV and LV production, the new era with VirusGENWebinarRegisterCell and gene therapy clinical trials and potential commercialization manufacturing require multiple, efficient viral vector production platforms at large-scale in a variety of cell culture platforms. Transient transfection can address this need while obtaining maximum yields and reducing costs. Mirus developed an advanced and versatile transfection formulation, “TransIT-VirusGEN". This novel technology is specifically designed for large-scale virus production to support the biopharmaceutical market’s need for highly efficient recombinant AAV and LV titers. This innovative system increases viral titers 2-10-fold over current technologies with complementary enhancers that provide better viral vector yields. Here, we highlight the benefits associated with using VirusGEN® like i) higher titers, ii) better quality vectors (i.e., better AAV percent full capsids), iii) compatibility with various cell culture adherent and suspension systems, iv) adaptability with a turnkey easy-to-follow workflow for scalability, and v) availability in a different configuration, permitting a seamless transition from process development to GMP. For more information, please contact us at webinar@avantorsciences.com Presented By: Hayder is a Field Application Scientist at Mirus. He has a Ph.D. in Gene Therapy from the University of London, where he studied the correction of the classical scid mouse (a model of hemopoietic inherited disorders) mutation by gene editing. He then pursued his postdoc studies in other inherited diseases in muscles, CNS, and liver using AAV and LV. He uses his previous on-bench experience together with his understanding of animal models for inherited diseases to help and support Mirus customers in the field. |
|
Processing your request... |
